Privi Speciality Chemicals (PRIVISCL) Q4 25/26 earnings summary

Executive summary

• Achieved total income of ₹2,583 crore in FY26, up 22% year-over-year, driven by robust volume growth and improved product mix.

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, were approved, with unmodified opinions from statutory auditors.

• Final dividend of Rs. 10 per equity share recommended for FY 2025-26, subject to shareholder approval.

• Re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for three years, effective August 13, 2026.

• Focused on value-added and specialty products, sustainability, and disciplined execution for long-term value creation.

Financial highlights

• FY26 revenue grew 21.7% year-over-year to ₹2,582.92 crore; Q4 revenue up 15.5% year-over-year to ₹725.70 crore.

• FY26 EBITDA rose 40.3% to ₹665.45 crore; Q4 EBITDA up 25.1% to ₹184.41 crore.

• PAT for FY26 increased 75.2% year-over-year to ₹327.54 crore; Q4 PAT up 40.9% to ₹93.7 crore.

• Consolidated revenue for FY 2025-26 was Rs. 2,56,368.55 lakhs, up from Rs. 2,10,119.09 lakhs year-over-year.

• Consolidated net profit for FY 2025-26 was Rs. 31,672.10 lakhs, compared to Rs. 18,475.03 lakhs in the previous year.

Outlook and guidance

• On track to achieve ₹5,000 crore revenue and ₹1,000+ crore EBITDA by FY29-30, targeting over 2x growth.

• EBITDA margins expected to remain above 20% due to operational efficiency and enhanced product mix.

• The Board recommended a final dividend of Rs. 10 per share for FY 2025-26, pending shareholder approval at the 41st AGM.